Anuh Pharma reported a 20% YoY decline in consolidated net profit to ₹41.05 crore for FY26, with revenue from operations at ₹772.56 crore.
The board recommended a final dividend of ₹1.50 per share (30% payout) and approved the re-appointment of two non-executive directors.
The company completed a 1:1 bonus share issuance in Q2 FY26 and appointed new internal and cost auditors for FY27.
Nine promoter group shareholders, holding a collective 0.95% stake, requested reclassification to the public category.